Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

Columnist Kristin Neva shares what she feels has worked and not worked in terms of slowing her husband's ALS progression over 15 years.

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.

Caregivers can keep communication going for people living with ALS by using tools, patience, and clear language.

The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more ...

AUT00201, an oral small molecule, reduced the loss of motor neurons and eased motor symptoms in a mouse model of ALS, a study ...

CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting ...

Guest writer Anita Newton recounts her struggle to access help for her husband's ALS during the height of COVID-19 ...

KLTO‑202 is an experimental gene therapy that would deliver the instructions for a protein that may reduce inflammation and ...

A noninvasive therapy delivering gentle spinal stimulation was shown to slow disease progression and extend survival in an ...